Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Operating Leases (2024 - 2025)

Maze Therapeutics has reported Operating Leases over the past 2 years, most recently at $18.5 million for Q4 2025.

  • Quarterly Operating Leases fell 15.89% to $18.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.5 million through Dec 2025, down 15.89% year-over-year, with the annual reading at $18.5 million for FY2025, 15.89% down from the prior year.
  • Operating Leases was $18.5 million for Q4 2025 at Maze Therapeutics, down from $19.4 million in the prior quarter.
  • Over five years, Operating Leases peaked at $22.0 million in Q4 2024 and troughed at $18.5 million in Q4 2025.